Non-peptide compounds, such as OTX008, have been designed to target Gal-1 based on the effect of anginex [87], which has been found to serve as a therapeutic reagent for cancer and diabetic patients [40,87,182,183,184]. This evidence concerns the gene LGALS1 and cancer.